Key stats
Market capitalization
1.232BUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
4.90
Basic EPS (TTM)
2.31USD
About Dynavax Technologies Corporation
ISIN
US2681582019
Sector
Health Technology
Industry
Biotechnology
Website
dynavax.com
CEO
Ryan Spencer
Headquarters
Emeryville
Employees
351
Founded
1996
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0